摘要
目的了解癌症合并糖尿病患者使用糖皮质激素(GC)后的血糖变化情况,探讨糖皮质激素在癌症合并糖尿病患者应用的可行性。方法回顾性分析我科收治的60例癌症合并2型糖尿病住院患者情况,将所有化疗期间使用激素的患者,作为观察组,化疗期间未使用激素的患者,作为对照组。结果与对照组比较,观察组空腹血糖的变化差异无统计学意义(t=0.036,P=0.971);与对照组比较,观察组午餐后2小时血糖的变化差异无统计学意义(t=1.013,P=0.315)。观察组使用糖皮质激素后有35例次患者需增加降糖药物,有14例次患者需增加胰岛素剂量,但未出现糖尿病酮症酸中毒等不良反应,血糖可以控制。结论 2型糖尿病合并癌症化疗期间,因治疗需要使用糖皮质激素是安全可行的,但需加强对血糖的监测,并及时给予增加降糖药物或胰岛素,避免发生糖尿病酮症酸中毒及高渗性昏迷等严重并发症。
Objective To investigate the change of the blood sugar in cancer patients with type 2 diabetes mellitus during the chemotherapy and determine the feasibility of using glucocorticoids Methods The changes of blood sugar in 60 cases of cancer patients with type 2 diabetes mellitus during the chemotherapy were analyzed retrospectively. Patients who used glu- cocorticoids were considered as observation group, and patients who didn＇t use glucocorticoids were considered as control group. Results Changes in fasting glucose hadn＇t statistical significance between observation group and control group （t= 0. 036, P= 0. 971）. Similarly, Changes in blood sugar 2 hours after lunch hadn＇t statistical significance （t=1. 013, P=0. 315）. In obser- vation group thirty-five cases needed to increase the amounts of hypoglyeemic agents and fourteen cases needed to increase the a- mounts of insulin . No one case appeared adverse reactions such as diabetic ketoacidosis, and the blood sugar could he con- trolled. Conclusion Using glucocorticoids in cancer patients with type 2 diabetes mellitus during the chemotherapy is safe and feasible. It is necessary to strengthen the monitoring of blood sugar and timely increase hypoglycemic agents and insulin in order to avoid diabetic ketoacidosis, hvoertonic coma and other serlnus enmnllrntlnn
出处
《福建医药杂志》
CAS
2013年第4期15-17,共3页
Fujian Medical Journal
关键词
癌症
2型糖尿病
糖皮质激素
cancer
type 2 diabetes mellitus
glucocorticoids
